Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : $1,920.0 million
Deal Type : Licensing Agreement
Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment
Details : Through the license agreement, Merck will gain global rights to develop and commercialize MK-5684 (opevesostat), which is being evaluated for metastatic castration-resistant prostate cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $290.0 million
July 01, 2024
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : $1,920.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Orion and MSD Initiate Two Phase 3 Trials Of ODM-208 in Prostate Cancer
Details : ODM-208/MK5684, a CYP11A1 inhibitor, is in Phase 3 trials for metastatic castration-resistant prostate cancer with hormone replacement.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : Opevesostat,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Opevesostat,Dexamethasone,Hydrocortisone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database
Details : ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as metastatic castration-resistant prostate cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Opevesostat,Dexamethasone,Hydrocortisone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $290.0 million
July 13, 2022
Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
Details : ODM-208 is a novel, oral, non-steroidal and selective inhibitor of CYP11A1 enzyme developed by Orion for the treatment of prostate cancer. ODM-208 suppresses the production of all steroid hormones and their precursors that may activate AR signalling path...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2022
Lead Product(s) : Opevesostat,Fludrocortisone Acetate,Glucocorticoid
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
